Lotus eye hospital and Institute Limited has received a disclosure from promoter Sangeetha Sundaramoorthy regarding a proposed share acquisition under Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction involves the acquisition of shares from fellow promoter Kavetha Sundaramoorthy through an inter-se transfer arrangement.

Transaction Details

The proposed acquisition involves significant changes in promoter shareholding structure. Key transaction parameters are outlined below:

The share purchase agreement was executed on June 2, 2025, establishing the framework for this promoter-to-promoter transfer. The transaction is structured under sub-clause 10(1)(a)(ii) of SEBI regulations, which provides exemption from mandatory open offer requirements for inter-se transfers between promoters.

Regulatory Compliance and Pricing

The acquisition price of Rs 70 per share is positioned favorably compared to market benchmarks. The 60-day volume weighted average market price stands at Rs 81.30, making the transaction price approximately 13.91% below the market average. This pricing structure ensures compliance with SEBI regulations requiring acquisition prices not to exceed 25% above the computed market price.

Sangeetha Sundaramoorthy has provided formal declarations confirming compliance with all applicable disclosure requirements under Chapter V of the Takeover Regulations, 2011. The acquirer has also confirmed that all conditions specified under regulation 10(1)(a) regarding exemptions have been duly satisfied.

Shareholding Impact

The transaction will result in a significant redistribution of promoter holdings within Lotus Eye Hospital and Institute Limited:

Post-transaction, Sangeetha Sundaramoorthy and persons acting in concert will hold 35.0084% of the company's total share capital, representing an increase of 6.8693 percentage points. Conversely, Kavetha Sundaramoorthy's shareholding will decrease by the same percentage, reducing her stake to 2.7456%.

Strategic Implications

This inter-se transfer represents a consolidation of promoter holdings, with Sangeetha Sundaramoorthy emerging as the dominant promoter stakeholder. The transaction maintains overall promoter control while redistributing ownership concentration within the promoter group. The structured approach through formal share purchase agreements and regulatory compliance demonstrates adherence to corporate governance standards and transparency requirements mandated by SEBI for substantial acquisitions.

Lotus Eye Hospital And Institute Limited has successfully concluded its postal ballot process with all three director appointments receiving overwhelming shareholder approval. The company announced the voting results on January 19, 2026, with all resolutions passed by a substantial majority of 99.07%.

Postal Ballot Voting Results

The e-voting process conducted through CDSL platform concluded on January 17, 2026, with strong shareholder participation. The voting results demonstrate unanimous support for the proposed director appointments:

Director Appointments Approved

All three special resolutions related to director appointments received identical voting results, reflecting strong shareholder confidence in the board composition.

Dr KS Ramalingam Appointments Confirmed

Shareholders approved both resolutions concerning Dr KS Ramalingam's directorship. The first resolution confirmed his continuation as Non-Executive Director from June 1, 2025, to February 8, 2026, while the second approved his fresh appointment from February 9, 2026, with retirement by rotation provisions.

Dr S Natesan Reappointed for Second Term

Dr S Natesan's reappointment as Independent Director for a second consecutive five-year term from January 3, 2026, to January 3, 2031, received strong shareholder endorsement.

Regulatory Compliance and Process

The postal ballot process was conducted in accordance with Section 110 of the Companies Act, 2013, and Regulation 44 of SEBI LODR 2015. The e-voting facility was exclusively provided through CDSL platform, with the voting period extending from December 19, 2025, to January 17, 2026.

The scrutinizer's report confirmed the fair and transparent conduct of the voting process, with all electronic data and records handed over to the company for safe keeping. The voting results have been communicated to both BSE and NSE as per regulatory requirements and made available on the company's website at www.lotuseye.org .